iGlarLixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L

por Niemoeller, Elisabeth, Souhami, Elisabeth, Wu, Yujun, Jensen, Klaus H.
Publicado 2017

Safety, tolerability and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open‐label, multicenter study

por Seino, Yutaka, Terauchi, Yasuo, Wang, Xiangling, Watanabe, Daisuke, Niemoeller, Elisabeth
Publicado 2017

Fixed‐ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß‐cell function in people with type 2 diabetes

por Ferrannini, Ele, Niemoeller, Elisabeth, Dex, Terry, Servera, Soraly, Mari, Andrea
Publicado 2022

Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-S

por Onishi, Yukiko, Niemoeller, Elisabeth, Ikeda, Yukio, Takagi, Hiroki, Yabe, Daisuke, Seino, Yutaka
Publicado 2015

Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Ora...

por Watada, Hirotaka, Takami, Akane, Spranger, Robert, Amano, Atsushi, Hashimoto, Yasuhiro, Niemoeller, Elisabeth
Publicado 2020

Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta‐analysis of 6‐month phase 3 clinical trials...

por Danne, Thomas, Matsuhisa, Munehide, Sussebach, Christian, Goyeau, Harmonie, Lauand, Felipe, Niemoeller, Elisabeth, Bolli, Geremia B.
Publicado 2020

Efficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulin‐naïve people with type 2 diabetes: The EDITION AP randomized controlled tr...

por Ji, Linong, Kang, Eun Seok, Dong, XiaoLin, Li, Ling, Yuan, GuoYue, Shang, Shuhua, Niemoeller, Elisabeth
Publicado 2019

Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial

por Frias, Juan Pablo, Choi, JaeDuk, Rosenstock, Julio, Popescu, Luiza, Niemoeller, Elisabeth, Muehlen-Bartmer, Isabel, Baek, Seungjae
Publicado 2022

Switching to iGlarLixi versus continuation of a daily or weekly glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in insufficiently controlled type 2 diabetes: A LixiLan‐G trial...

por Rosenstock, Julio, Blonde, Lawrence, Aroda, Vanita R., Frias, Juan, Souhami, Elisabeth, Ji, Chen, Niemoeller, Elisabeth, Del Prato, Stefano
Publicado 2021

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)

por Riddle, Matthew C., Aronson, Ronnie, Home, Philip, Marre, Michel, Niemoeller, Elisabeth, Miossec, Patrick, Ping, Lin, Ye, Jenny, Rosenstock, Julio
Publicado 2013

Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiL...

por Davies, Melanie J., Rosenstock, Julio, Ali, Amar, Russell‐Jones, David, Souhami, Elisabeth, Palmer, Karen, Ji, Chen, Niemoeller, Elisabeth, Skolnik, Neil
Publicado 2021

Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study

por Blonde, Lawrence, Rosenstock, Julio, Frias, Juan, Birkenfeld, Andreas L., Niemoeller, Elisabeth, Souhami, Elisabeth, Ji, Chen, Del Prato, Stefano, Aroda, Vanita R.
Publicado 2021

A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes

por Barrientos‐Pérez, Margarita, Hsia, Daniel S., Sloan, Lance, Nell, Haylene, Mungur, Ounisha, Hovsepian, Lionel, Schmider, Wolfgang, Spranger, Robert, Yang, Na, Niemoeller, Elisabeth
Publicado 2022

Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus...

por Yuan, Xiaoyong, Guo, Xiaohui, Zhang, Junqing, Dong, Xiaolin, Lu, Yibing, Pang, Wuyan, Gu, Shenghong, Niemoeller, Elisabeth, Ping, Lin, Nian, Gaowei, Souhami, Elisabeth
Publicado 2022

Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes...

por Rosenstock, Julio, Aronson, Ronnie, Grunberger, George, Hanefeld, Markolf, Piatti, PierMarco, Serusclat, Pierre, Cheng, Xi, Zhou, Tianyue, Niemoeller, Elisabeth, Souhami, Elisabeth, Davies, Melanie
Publicado 2017

Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6–17 years) With Type 1 Diabetes: Results...

por Danne, Thomas, Tamborlane, William V., Malievsky, Oleg A., Franco, Denise R., Kawamura, Tomoyuki, Demissie, Marek, Niemoeller, Elisabeth, Goyeau, Harmonie, Wardecki, Marek, Battelino, Tadej
Publicado 2020

Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed‐ratio combination) vs insulin glargine across...

por Wysham, Carol, Bonadonna, Riccardo C., Aroda, Vanita R., Puig Domingo, Manuel, Kapitza, Christoph, Stager, William, Yu, Christine, Niemoeller, Elisabeth, Souhami, Elisabeth, Bergenstal, Richard M.
Publicado 2017

Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan‐O trial testing a titratable fixed‐ratio combination of insulin g...

por Davies, Melanie J., Leiter, Lawrence A., Guerci, Bruno, Grunberger, George, Ampudia‐Blasco, F. Javier, Yu, Christine, Stager, William, Niemoeller, Elisabeth, Souhami, Elisabeth, Rosenstock, Julio
Publicado 2017

Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and...

por Aroda, Vanita R., Rosenstock, Julio, Wysham, Carol, Unger, Jeffrey, Bellido, Diego, González-Gálvez, Guillermo, Takami, Akane, Guo, Hailing, Niemoeller, Elisabeth, Souhami, Elisabeth, Bergenstal, Richard M.
Publicado 2017

Impact of disease duration and β‐cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Explorat...

por Del Prato, Stefano, Frias, Juan Pablo, Blonde, Lawrence, Aroda, Vanita R., Shehadeh, Niam, Saremi, Aramesh, Dex, Terry, Niemoeller, Elisabeth, Souhami, Elisabeth, Liu, Minzhi, Rosenstock, Julio
Publicado 2020